Intismeran autogene

Intismeran autogene (V940 / mRNA-4157) is Moderna and Merck's personalized neoantigen mRNA cancer vaccine - each shot custom-built from a patient's own tumor DNA, paired with Keytruda (pembrolizumab) to keep T cells active. After a Phase 2b adjuvant melanoma readout (adjuvant = given after surgery to reduce recurrence risk) cut the risk of recurrence or death roughly 44% versus pembrolizumab alone (hazard ratio ~0.56, 95% CI ~0.31-1.02 at primary analysis; HR ~0.49 at the 3-year update) [1][6], the program now sits across four confirmed Phase 3 trials spanning adjuvant melanoma and non-small cell lung cancer (NSCLC), with Phase 2 programs in muscle-invasive bladder cancer and metastatic squamous NSCLC [2]. NCT06077760 is the resected NSCLC Phase 3 (V940-002, 868 patients) [2]. If the platform works, it extends Merck's ~$30B Keytruda franchise into a defensible, manufacturing-moated combination just as biosimilars approach late this decade [3]. If it fails in Phase 3 melanoma, the whole personalized neoantigen thesis takes a serious hit.

Phase 3 across multiple solid tumors. The FDA granted Breakthrough Therapy Designation in February 2023 for adjuvant (post-surgical) high-risk Stage IIB-IV melanoma based on the KEYNOTE-942 Phase 2b results [4]. Merck exercised its option on the program in October 2022 for $250M, splitting costs and profits 50/50 with Moderna [5]. The lead Phase 3 is INTerpath-001 (NCT05933577) in adjuvant melanoma; NCT06077760 (this node) is the adjuvant NSCLC Phase 3 (V940-002, Stage II-IIIB resected disease) [2][8]. Additional Phase 3 programs disclosed by Merck include V940-009 in adjuvant NSCLC and V940-014 in high-risk Stage I NSCLC, plus Phase 2 reads in muscle-invasive bladder cancer (V940-011, combined with BCG - Bacillus Calmette-Guérin, a decades-old bladder cancer immunotherapy) and metastatic squamous NSCLC (V940-013) [2]. The first Phase 3 readout will almost certainly come from melanoma - INTerpath-001 began enrolling in 2023 with a target of ~1,089 patients and primary completion currently posted in the 2029 range on ClinicalTrials.gov, but disease-free survival events accrue faster in high-risk melanoma, so an interim or first analysis is plausible in the 2027-2028 window (no interim has been announced as of Q1 2026) [8]. The NSCLC trial in this node is likely a 2027-2028 readout window at earliest.

The vaccine teaches a patient's own immune cells to recognize mutated proteins that exist only inside their tumor. Researchers sequence the tumor and a matched normal tissue sample, software predicts which mutations will produce "neoantigens" - protein fragments the immune system can see as foreign - and up to 34 of these are concatenated as short peptide sequences (not full proteins) onto a single polyepitope mRNA strand wrapped in lipid nanoparticles (the same delivery system as the COVID vaccines). Once injected, the patient's own cells translate the mRNA, display the neoantigen fragments, and T cells learn that fingerprint. But a vaccine alone trains T cells that can't overcome the tumor's active suppression machinery - tumors use the PD-1/PD-L1 pathway to switch off T cells on contact. Pembrolizumab blocks PD-1, giving the trained T cells a fighting chance to actually kill tumor cells [6]. The mechanism is plausible and supported by real human data. KEYNOTE-942 showed a hazard ratio of ~0.56 (95% CI ~0.31-1.02) for recurrence-free survival versus pembrolizumab alone at primary analysis, tightening to HR ~0.49 (95% CI ~0.27-0.88) at the 3-year update with a directionally favorable but underpowered overall survival trend [1][6]. BioNTech and Genentech reported a similar T-cell expansion signal in pancreatic cancer with autogene cevumeran, an independent platform using the same neoantigen-vaccine logic [7]. The mechanism is no longer speculative - but no personalized neoantigen vaccine has yet succeeded in Phase 3.

NCT06077760 (V940-002) is a randomized, double-blind Phase 3 enrolling 868 patients with completely resected, margin-negative Stage II, IIIA, or IIIB NSCLC who have already received platinum-based adjuvant chemotherapy [2]. Patients receive intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab - meaning the comparator is the current standard of care (adjuvant Keytruda was approved in resected NSCLC in 2023). Primary endpoint is disease-free survival. Merck Sharp & Dohme is the sponsor of record (the asset itself is jointly developed with Moderna). Recruiting. The design is clean: well-defined population, on-label combination, the right comparator, and a clinically meaningful endpoint. The vaccine itself is biomarker-driven by construction - each patient gets a product made from their own tumor mutations, so the trial does not pre-select on tumor mutational burden (TMB) or PD-L1 status. The main design weakness is the DFS endpoint timing: adjuvant trials require event accrual, so even with full enrollment, primary analysis is years out. Merck is running parallel Phase 3s (V940-009 in NSCLC, V940-014 in early-stage NSCLC, INTerpath-001 in melanoma), which means platform risk is concentrated upstream - if KEYNOTE-942 doesn't replicate in melanoma Phase 3, this trial's result becomes academic.

Our model gives this drug a 29% chance of eventually being approved. That figure starts from the historical approval rate for Phase 3 drugs in this area - about 48% - then shifts based on ten specific facts about the trial and its sponsor. The estimate is helped by more secondary endpoints than usual, larger-than-typical enrollment, and the sponsor's strong track record of approvals, but pulled down by weak or limited results from earlier-phase testing. The remaining factors are close to average for this stage, so they leave the number roughly where it started.

Efficacy. KEYNOTE-942 was n=157 and randomized 2:1 - a strong signal but a small trial with wide CIs (primary HR CI crossed 1.0). Phase 3 effect sizes routinely shrink. Even if the melanoma readout holds, the NSCLC and renal cell carcinoma (RCC) settings have meaningfully different immune biology. NSCLC has higher average tumor mutational burden (TMB) but more heterogeneous T-cell infiltration; RCC has unusually low TMB and historically odd immuno-oncology (IO) response patterns. A platform that works in melanoma may not translate evenly. Safety. The vaccine plus pembrolizumab combination raises immune-related adverse event risk above pembrolizumab alone. KEYNOTE-942 reported a manageable profile, but Phase 3 populations include more comorbidities. No mechanism-based showstopper has surfaced. Execution. This is the unique risk. Every dose is custom: biopsy, sequence, predict neoantigens, manufacture mRNA, encapsulate in lipid nanoparticles (LNPs), ship cold-chain - per patient. Turnaround in KEYNOTE-942 was reported around 9 weeks from biopsy to first dose. Scaling that to tens of thousands of patients across global indications is genuinely unprecedented. Moderna's mRNA manufacturing is mature, but bespoke per-patient throughput at commercial scale has never been done. Commercial. Pricing will be high - likely six figures per course. Payer coverage for an add-on to already-expensive pembrolizumab depends entirely on the magnitude of DFS or overall survival benefit shown in Phase 3.

Watch this closely. INTerpath-001 - the adjuvant melanoma Phase 3 (NCT05933577) - is the platform-defining event, not the NSCLC trial in this node. A positive melanoma readout opens the whole solid-tumor pipeline; a miss probably ends the personalized neoantigen vaccine thesis regardless of how many Phase 3s Merck is running in parallel. The specific signal worth tracking: any interim analysis, event-accrual update, or enrollment-completion announcement from INTerpath-001. Based on 2023 enrollment start, target ~1,089 patients, and event-driven DFS analysis in high-risk Stage IIB-IV melanoma, an interim/first analysis is plausible in the 2027-2028 window; no interim has been announced as of Q1 2026 [8]. Merck typically previews late-stage oncology trial timing on Q4 and Q1 earnings calls [3]. Commercial gravity: Merck's 2024 revenue was approximately $63.6B [3], with Keytruda at roughly $29.5B annualized - about 46% of total revenue. Intismeran is Merck's bet on extending the Keytruda franchise into adjuvant durability before Keytruda's IP cliff begins biting around 2028. For Moderna, the economics matter more: $250M option milestone plus 50/50 profit share on what analysts have modeled as a potential multi-billion-dollar franchise across indications would be a meaningful contributor to Moderna's post-COVID revenue trajectory, though not transformational in the way COVID vaccines were. Check back when the first INTerpath-001 interim or readout drops - that's the platform-defining moment. The NSCLC Phase 3 in this node only matters if melanoma works first.